European Radiology:定量MRCP(MRCP+)对原发性硬化性胆管炎风险分层的评价

2022-01-20 shaosai MedSci原创

原发性硬化性胆管炎(PSC)是一种进展性的肝脏和胆道自身免疫性疾病,在男性中更为流行,一般与炎症性肠病(IBD)有关。

原发性硬化性胆管炎(PSC)是一种进展性的肝脏和胆道自身免疫性疾病,在男性中更为流行,一般与炎症性肠病(IBD)有关。疾病的病理特征是造成胆管的局灶性狭窄和扩张,最终导致继发性肝硬化和肝胆肿瘤的发生。到目前为止,PSC还没有有效的治疗方法,在大多数情况下会发展成肝衰竭,甚至导致死亡或肝移植。

PSC的诊断主要通过磁共振胆囊造影(MRCP)来确定,通常不需要结合患者的临床和生化情况进行肝脏活检,因此存在较大的局限性。MRCP是目前一线的无创诊断工具,基本上只能对胆道树进行定性评估,而这种评估往往受制于观察者之间的差异。现阶段临床上建立了ANALI 1和2分数MRCP图像提供一个标准化的判析结构。尽管这些分数已被证明与影像学疾病进展和临床预后有关,但其仍不能克服MRCP的定性性质。最近,有学者建议使用一种半自动软件,对三维MRCP图像进行定量分析(MRCP+),以提供更准确的诊断和评估

近日,发表在European Radiology杂志的一项研究通过评估各种MRCP+参数与已建立的生化风险评分(MRS、AOPI和PREsTo)的关联,评估其对患者临床风险分层的能力同时还评估了MRCP+与MRE的性能,以评估MRCP+与现有形态学MRCP评分(如ANALI 1和ANALI 2)结合使用时的附加价值为临床提供了一种能够精确量化胆管潜狭窄和扩张的影像学技术有助于实现疾病的有效管理肿瘤监测

本研究于2014年1月至2015年12月期间回顾性评估了65名PSC患者的MRI图像、通过MRE测量肝脏硬度以及生化检测。MRCP+被用来对MRCP图像进行后处理,以获得胆管和胆道树的定量测量。线性回归分析被用来检验关联。采用Bootstrapping作为验证方法。 

节段性狭窄的总数与Mayo风险评分的关联最强(R2 = 0.14),最小狭窄直径与Amsterdam Oxford预后指数的关联最高(R2 = 0.12),宽度为0-3毫米的胆管结节百分比与PSC风险估计工具的关联最强(R2 = 0.09)。存在中位数>9毫米的胆管与MRE的关联度最高(R2=0.21)。MRCP+与Mayo风险评分的关联强度与ANALI2相当,弱于MRE(分别为R2=0.23,0.24,0.38)。MRCP+增强了ANALI 2和MRE与Mayo风险评分的关联。 

 低(A-D)和高(E-H)Mayo风险分数的PSC患者,展示了MRCP(A,E)、MRE(B,F)、MRCP+(C,G)和MRCP+(E,H)得出的胆管差异。Mayo风险评分高的患者在MRCP和MRCP+上显示出更大的弥漫性肝内胆管狭窄,在MRE上肝脏硬度增加,在MRCP+上胆管树体积增加。

本研究表明,MRCP+参数可通过与生化风险评分、ANALI和MRE的联系对PSC患者进行风险分层。此外,MRCP+与ANALI和MRE的结合改善了与MRS的关联。最后,MRE和MRCP+的结合可以对诊断时和随后的随访中用于评估PSC的胆管和肝脏部分的影像学证据进行客观量化。

原文出处:

Marwa F Ismail,Gideon M Hirschfield,Bettina Hansen,et al.Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores.DOI:10.1007/s00330-021-08142-y

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1847021, encodeId=629c184e02157, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 16 01:40:43 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729315, encodeId=17e41e29315b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 29 20:40:43 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360992, encodeId=71c2136099266, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423938, encodeId=58e51423938f5, content=<a href='/topic/show?id=219d3e07851' target=_blank style='color:#2F92EE;'>#原发性硬化性胆管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37078, encryptionId=219d3e07851, topicName=原发性硬化性胆管炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c83872517, createdName=weihongyv, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444750, encodeId=42a21444e5010, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496396, encodeId=c3961496396ed, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628506, encodeId=e7fe162850630, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1847021, encodeId=629c184e02157, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 16 01:40:43 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729315, encodeId=17e41e29315b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 29 20:40:43 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360992, encodeId=71c2136099266, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423938, encodeId=58e51423938f5, content=<a href='/topic/show?id=219d3e07851' target=_blank style='color:#2F92EE;'>#原发性硬化性胆管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37078, encryptionId=219d3e07851, topicName=原发性硬化性胆管炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c83872517, createdName=weihongyv, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444750, encodeId=42a21444e5010, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496396, encodeId=c3961496396ed, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628506, encodeId=e7fe162850630, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-29 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1847021, encodeId=629c184e02157, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 16 01:40:43 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729315, encodeId=17e41e29315b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 29 20:40:43 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360992, encodeId=71c2136099266, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423938, encodeId=58e51423938f5, content=<a href='/topic/show?id=219d3e07851' target=_blank style='color:#2F92EE;'>#原发性硬化性胆管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37078, encryptionId=219d3e07851, topicName=原发性硬化性胆管炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c83872517, createdName=weihongyv, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444750, encodeId=42a21444e5010, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496396, encodeId=c3961496396ed, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628506, encodeId=e7fe162850630, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1847021, encodeId=629c184e02157, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 16 01:40:43 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729315, encodeId=17e41e29315b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 29 20:40:43 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360992, encodeId=71c2136099266, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423938, encodeId=58e51423938f5, content=<a href='/topic/show?id=219d3e07851' target=_blank style='color:#2F92EE;'>#原发性硬化性胆管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37078, encryptionId=219d3e07851, topicName=原发性硬化性胆管炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c83872517, createdName=weihongyv, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444750, encodeId=42a21444e5010, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496396, encodeId=c3961496396ed, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628506, encodeId=e7fe162850630, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1847021, encodeId=629c184e02157, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 16 01:40:43 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729315, encodeId=17e41e29315b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 29 20:40:43 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360992, encodeId=71c2136099266, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423938, encodeId=58e51423938f5, content=<a href='/topic/show?id=219d3e07851' target=_blank style='color:#2F92EE;'>#原发性硬化性胆管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37078, encryptionId=219d3e07851, topicName=原发性硬化性胆管炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c83872517, createdName=weihongyv, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444750, encodeId=42a21444e5010, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496396, encodeId=c3961496396ed, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628506, encodeId=e7fe162850630, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-22 huagfeg
  6. [GetPortalCommentsPageByObjectIdResponse(id=1847021, encodeId=629c184e02157, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 16 01:40:43 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729315, encodeId=17e41e29315b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 29 20:40:43 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360992, encodeId=71c2136099266, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423938, encodeId=58e51423938f5, content=<a href='/topic/show?id=219d3e07851' target=_blank style='color:#2F92EE;'>#原发性硬化性胆管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37078, encryptionId=219d3e07851, topicName=原发性硬化性胆管炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c83872517, createdName=weihongyv, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444750, encodeId=42a21444e5010, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496396, encodeId=c3961496396ed, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628506, encodeId=e7fe162850630, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1847021, encodeId=629c184e02157, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Nov 16 01:40:43 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729315, encodeId=17e41e29315b9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Jan 29 20:40:43 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360992, encodeId=71c2136099266, content=<a href='/topic/show?id=e372100861dc' target=_blank style='color:#2F92EE;'>#风险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100861, encryptionId=e372100861dc, topicName=风险分层)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423938, encodeId=58e51423938f5, content=<a href='/topic/show?id=219d3e07851' target=_blank style='color:#2F92EE;'>#原发性硬化性胆管炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37078, encryptionId=219d3e07851, topicName=原发性硬化性胆管炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7c83872517, createdName=weihongyv, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444750, encodeId=42a21444e5010, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496396, encodeId=c3961496396ed, content=<a href='/topic/show?id=43b6e358710' target=_blank style='color:#2F92EE;'>#硬化性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73587, encryptionId=43b6e358710, topicName=硬化性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1628506, encodeId=e7fe162850630, content=<a href='/topic/show?id=9a4e83503e4' target=_blank style='color:#2F92EE;'>#胆管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83503, encryptionId=9a4e83503e4, topicName=胆管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c21721182790, createdName=cmj15wellington, createdTime=Sat Jan 22 01:40:43 CST 2022, time=2022-01-22, status=1, ipAttribution=)]

相关资讯

Gastroenterology:伴有原发性硬化性胆管炎的炎症性肠病患者的预后研究

伴有原发性硬化性胆管炎的炎症性肠病患者其结肠癌、肝胰胆管癌和死亡风险增加。40岁及以下、男性以及非洲加勒比裔人群的预后较差。

Clin Gastroenterol H:他汀类药物与原发性硬化性胆管炎患者结局改善相关

由此可见,在瑞典患有PSC的基于人群的患者队列中,研究人员将他汀类药物和硫唑嘌呤的使用与死亡以及死亡或肝移植风险降低联系在一起。接触熊去氧胆酸与死亡率降低无关。

J hepatology:熊去氧胆酸预防性治疗对原发性胆源性胆管炎的长期影响

肝移植(LT)后原发性胆源性胆管炎(PBC)的复发很常见。熊去氧胆酸(UDCA)是目前PBC的标准疗法。本项研究旨在探究预防性使用UDCA对LT后PBC复发的发生率和长期后果的影响。

Hanmi的NASH候选药物HM15211治疗硬化性胆管炎,获得FDA孤儿药称号

Hanmi Pharmaceutical公司表示,其非酒精性脂肪性肝炎候选药物HM15211获得FDA孤儿药称号,用于治疗原发性硬化性胆管炎。

2019 BSG/UK-PSC指南:原发性硬化性胆管炎的诊断和治疗

2019年6月,英国胃肠病学会(BSG)发布了原发性硬化性胆管炎的诊断和治疗指南,引起胆管疾病的原因有很多,这些原因应考虑作为评估胆管狭窄患者的因素。本文主要针对原发性硬化性胆管炎的诊断和治疗提出指导建议,目的是为临床医生在管理这类疾病的患者时提供循证指导。

欧盟授予CM-101治疗原发性硬化性胆管炎的孤儿药资格

原发性硬化性胆管炎(primary sclerosing cholangitis, PSC)是一种不明病因的慢性进展性疾病,其特征是肝内和/或肝外胆道系统内中型和大型胆管发生炎症、纤维化及狭窄。英国一